27285-09-2

Usage

Uses

Used in Pharmaceutical Industry:
1,2,3,4,5,6,7,8-OCTAHYDROBENZO[4,5]THIENO[2,3-D]PYRIMIDINE-2,4-DIONE is used as a pharmaceutical compound for its potential biological activity. Its unique molecular structure enables it to interact with specific biological targets, making it a promising candidate for the development of new drugs and therapeutic agents.
Used in Drug Discovery:
1,2,3,4,5,6,7,8-OCTAHYDROBENZO[4,5]THIENO[2,3-D]PYRIMIDINE-2,4-DIONE is used as a starting material in drug discovery for its potential to form new compounds with therapeutic properties. Its unique structure and ability to interact with biological targets make it a valuable component in the synthesis of novel drug candidates.
Used in Medicinal Chemistry Research:
1,2,3,4,5,6,7,8-OCTAHYDROBENZO[4,5]THIENO[2,3-D]PYRIMIDINE-2,4-DIONE is used as a research tool in medicinal chemistry to study its interactions with biological targets and understand its potential therapeutic effects. This knowledge can help in the design and development of new drugs with improved efficacy and safety profiles.

InChI:InChI=1/C10H10N2O2S/c13-8-7-5-3-1-2-4-6(5)15-9(7)12-10(14)11-8/h1-4H2,(H2,11,12,13,14)

Upstream product

• 27285-13-8 2-(3-phenylurea)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxamide 
• 40277-35-8 2,4-dichloro-5,6,7,8-tetrahydrobenzothieno<2,3-d>pyrimidine 
• 53162-03-1 Potassium; 4-oxo-3,4,5,6,7,8-hexahydro-benzo[4,5]thieno[2,3-d]pyrimidine-2-thiolate 
• 1312367-11-5 methyl 2-ureido-4,5,6,7-tetrahydrobenzo[b]thiophen-3-carboxylate 
• 108354-78-5 methyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate 
• 4506-71-2 ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate 
• 57-13-6 urea 
• 108-94-1 cyclohexanone 
• 100068-52-8 2-Aminocarbonylamino-3-ethoxycarbonyl-4,5,6,7-tetrahydro-1-benzothiophene 
• 75-44-5 phosgene 
• 4815-28-5 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxamide 
• 27285-10-5 2-ethoxycarbonylamino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-carboxamide 

Downstream Products

• 40277-35-8 2,4-dichloro-5,6,7,8-tetrahydrobenzothieno<2,3-d>pyrimidine 

Relevant academic research and scientific papers

FLT3 INHIBITORS AND USES THEREOF

The present invention provides methods of using compounds of formula I: or compositions thereof for the inhibition of FLT3, and the treatment of FLT3-mediated disorders.

IRAK INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

IRAK INHIBITORS AND USES THEREOF

The present invention provides arylo-fused thienopyrimidine compounds, compositions thereof, and methods of using the same.

Selective kainate receptor (GluK1) ligands structurally based upon 1H-cyclopentapyrimidin-2,4(1 H,3 H)-dione: Synthesis, molecular modeling, and pharmacological and biostructural characterization

The physiological function of kainate receptors (GluK1-GluK5) in the central nervous system is not fully understood yet. With the aim of developing potent and selective GluK1 ligands, we have synthesized a series of new thiophene-based GluK1 agonists (6a-c) and antagonists (7a-d). Pharmacological evaluation revealed that they are selective for the GluK1 subunit, with 7b being the most subtype-selective ligand reported to date (GluK1 vs GluK3). The antagonist 7a was cocrystallized with the GluK1 ligand binding domain, and an X-ray crystallographic analysis revealed the largest flexibility in GluK1 ligand binding domain opening upon binding of a ligand seen to date. The results provide new insights into the molecular mechanism of GluK1 receptor ligand binding and pave the way to the development of new tool compounds for studying kainate receptor function.

[[(Arylpiperazinyl)alkyl]thio]thieno[2,3-d]pyrimidinone derivatives as high-affinity, selective 5-HT(1A) receptor ligands

A series of 2-[[(4-aryl-1-piperazinyl)alkyl]thio]thieno[2,3- d]pyrimidin-4(1H)-one and 3-substituted 2-[[(4-aryl-1- piperazinyl)alkyl]thio]thieno[2,3-d]pyrimidin-4(3H)-one derivatives was prepared and evaluated for in vitro 5-HT(1A) receptor affinity by radioligand binding assays; the selectivity for 5-HT(1A) receptors rather than α1- adrenoceptors was also examined (ratio of the IC50 α1 to IC50 5- HT(1A)). The binding tests gave indications about the best features of the [(arylpiperazinyl)alkyl]thio moiety and of the substituents on the thiophene and pyrimidinone rings for efficacious and selective 5-HT(1A) ligands. The most effective derivative for displacing [3H]-8-OH-DPAT from rat hippocampal membranes was the 3-amino-2-[[3-[4-(2-methoxyphenyl)-1- piperazinyl]propyl]thio]-5,6-dimethylthieno[2,3-d]pyrimidin-4(3H)-one (70) (IC50 = 0.3 nM) with selectivity of 24 for the 5-HT(1A) over the α1- adrenoceptor. Compound 73, where the 2-methoxyphenyl on the N4 piperazine ring was replaced with a pyrimidine group, showed the best selectivity, with a ratio of 74, while its affinity IC50 for 5-HT(1A) was 6.8 nM. These results, compared to those for compounds 40 (IC50 24 nM; selectivity 2) and 49 (IC50 226 nM; selectivity 5), N3 unsubstituted analogues of derivatives 70 and 73, show the importance of an amino group in position 3 of the thienopyrimidine system for the interaction with 5-HT(1A) receptor binding sites, although this fragment can affect the affinity and selectivity only if linked to the (arylpiperazinyl)alkyl moiety. The better selectivity of piperidine 74 (IC50 0.8; selectivity 45) compared to the analogous piperazine 70 is also noteworthy. Twenty of the 30 molecules used for determining the binding affinity to 5-HT(1A) and α1-adrenergic receptors were selected for QSAR analysis using a series of molecular descriptors and calculated with the TSAR software.

Thieno Compounds. Part 5: Basically Substituted Thienopyrimidines

Derivatives of Thienopyrimidine are the analogous structures of quinazolines, which are used in therapy, especially against hypertonia.Some new basically substituted thienopyrimidines were synthesized from 3,4-dihydro-4-oxothienopyrimidines with 4-chlorothienopyrimidines as intermediates.The corresponding 2,4-dibasic derivatives were received in the same way by transformation of the 1,2,3,4-tetrahydro-2,4-dioxothienopyrimidines.Derivatives with two different basic groups were obtained by a step-wise substitution of the both chlorine-atoms.I the case of a reaction with an aliphatic amine to substitute the chlorine in position 4 followed by a reaction with an aromatic amine both the chlorine in position 2 and the basic group in position 4 are replaced.